摘要
目的探讨CYP2C19基因多态性与幽门螺杆菌(Helicobacter pylori,Hp)感染后胃癌易感性。方法选择2015年4月-2018年4月北京市和平里医院收治的原发性胃癌患者119例作为胃癌组,同期收治的慢性胃炎患者100例作为对照组,检测两组患者幽门螺杆菌感染情况,并分析胃癌组与对照组患者CYP2C19基因多态性,以及Hp阳性胃癌组与Hp阳性对照组CYP2C19基因多态性。结果胃癌组患者Hp感染率为73.11%(87/119),对照组患者Hp感染率为63.00%(63/100),两组Hp感染率比较无显著差异。胃癌组患者中纯合子快代谢型33例(27.73%)、杂合子快代谢型47例(39.50%)、慢代谢型39例(32.77%),对照组患者中纯合子快代谢型31例(31.00%)、杂合子快代谢型42例(42.00%)、慢代谢型27例(27.00%),两组患者CYP2C19基因型分布比较差异无统计学意义。Hp阳性胃癌患者中纯合子快代谢型20例(22.99%)、杂合子快代谢型37例(42.53%)、慢代谢型35例(40.23%),Hp阳性对照组患者中纯合子快代谢型19例(30.16%)、杂合子快代谢型29例(46.03%)、慢代谢型15例(23.81%),两组Hp阳性患者CYP2C19基因型分布比较差异有统计学意义(P<0.05),其中Hp阳性胃癌患者慢代谢型患者构成比高于Hp阳性对照组。结论 CYP2C19慢代谢型可增加Hp阳性患者胃癌发生风险,需引起临床工作者的重视。
OBJECTIVE To explore the CYP2 C19 gene polymorphism and susceptibility to gastric cancer after Helicobacter pylori infection. METHODS A total of 119 patients with primary gastric cancer who were treated in Beijing Hepingli Hospital from Apr 2015 to Apr 2018 were assigned as the gastric cancer group, meanwhile, 100 patients with chronic gastritis were set as the control group.The prevalence of H. pylori infection was detected, and the CYP2 C19 gene polymorphism was observed between the gastric cancer group and the control group as well as between the H. pylori-positive gastrin cancer group and the H. pylori-positive control group. RESULTS The incidence rate of H. pylori infection was 73.11%(87/119) in the gastric cancer group, 63.00%(63/100) in the control group, and there was no significant difference in the incidence rate of H. pylori infection between the two groups.Among the patients of the gastric cancer group, there were 33(27.73%)cases of homozygous fast metabolizers, 47(39.50%)cases of heterozygous fast metabolizers and 39(32.77%) cases of slow metabolizers;there were 31(31.00%)cases of homozygous fast metabolizers, 42(42.00%)cases of heterozygous fast metabolizers and 27(27.00%) cases of slow metabolizers in the control group, and there were no significant differences in the distribution of CYP2 C19 genotypes between the two groups of patients.There were 20(22.99%) cases of homozygous fast metabolizers, 30(34.48%)cases of heterozygous fast metabolizers and 37(42.53%) cases of slow metabolizers among the H. pylori-positive gastric cancer patients, while there were 19(30.16%)cases of homozygous fast metabolizers, 29(46.03%)cases of heterozygous fast metabolizers and 15(23.81%) cases of slow metabolizers among the H. pylori-positive patients of the control group, and there were significant differences in the distribution of CYP2 C19 genotypes between the two groups of H. pylori-positive patients(P<0.05);the percentage of slow metabolizers was higher among the H. pylori-positive gastric cancer patients than a
作者
汪湃
冯世兵
晋颖
WANG Pai;FENG Shi-bing;JIN Ying(Beijing Hepingli Hospital,Beijing 100013,China)
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2020年第2期170-173,共4页
Chinese Journal of Nosocomiology
基金
北京市和平里医院科研项目(2017-1-03)。
